Innate Pharma SA Retained Earnings Excluding Profit Loss For Reporting Period
Innate Pharma SA (IPHYF) had Retained Earnings Excluding Profit Loss For Reporting Period of -EUR 386.37 million as of 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Notes
ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod · last filed 2026-04-01
- 2025-12-31: Retained Earnings Excluding Profit Loss For Reporting Period -386.37M EUR.
- 2025-06-30: Retained Earnings Excluding Profit Loss For Reporting Period -386.36M EUR.
- 2024-12-31: Retained Earnings Excluding Profit Loss For Reporting Period -336.89M EUR.
- 2024-06-30: Retained Earnings Excluding Profit Loss For Reporting Period -336.89M EUR.
| Period end | Retained Earnings Excluding Profit Loss For Reporting Period |
|---|---|
| 2025-12-31 | -386.37M EUR 20-F · filed 2026-04-01 |
| 2025-06-30 | -386.36M EUR 6-K · filed 2025-09-17 |
| 2024-12-31 | -336.89M EUR 20-F · filed 2026-04-01 |
| 2024-06-30 | -336.89M EUR 6-K · filed 2024-09-12 |
| 2023-12-31 | -329.32M EUR 20-F · filed 2026-04-01 |
| 2023-06-30 | -330.31M EUR 6-K · filed 2023-09-14 |
| 2022-12-31 | -272.21M EUR 6-K · filed 2023-09-14 |
| 2022-06-30 | -272.24M EUR 6-K · filed 2022-09-15 |
| 2021-12-31 | -219.40M EUR 6-K · filed 2022-09-15 |